Basilea Pharmaceutica Ag Stock Current Valuation
BPMUF Stock | USD 44.45 0.00 0.00% |
Valuation analysis of Basilea Pharmaceutica helps investors to measure Basilea Pharmaceutica's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Basilea Pharmaceutica's price fluctuation is very steady at this time. Calculation of the real value of Basilea Pharmaceutica is based on 3 months time horizon. Increasing Basilea Pharmaceutica's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Basilea Pharmaceutica AG is useful when determining the fair value of the Basilea pink sheet, which is usually determined by what a typical buyer is willing to pay for full or partial control of Basilea Pharmaceutica. Since Basilea Pharmaceutica is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Basilea Pink Sheet. However, Basilea Pharmaceutica's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. Historical | Market 44.45 | Real 42.56 | Hype 44.45 | Naive 43.44 |
The real value of Basilea Pink Sheet, also known as its intrinsic value, is the underlying worth of Basilea Pharmaceutica Company, which is reflected in its stock price. It is based on Basilea Pharmaceutica's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Basilea Pharmaceutica's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Basilea Pharmaceutica's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Basilea Pharmaceutica AG helps investors to forecast how Basilea pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Basilea Pharmaceutica more accurately as focusing exclusively on Basilea Pharmaceutica's fundamentals will not take into account other important factors: Basilea Pharmaceutica AG Company Current Valuation Analysis
Basilea Pharmaceutica's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Basilea Pharmaceutica Current Valuation | 724.26 M |
Most of Basilea Pharmaceutica's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Basilea Pharmaceutica AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition |
In accordance with the recently published financial statements, Basilea Pharmaceutica AG has a Current Valuation of 724.26 M. This is 94.96% lower than that of the Healthcare sector and 84.41% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 95.64% higher than that of the company.
Basilea Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Basilea Pharmaceutica's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Basilea Pharmaceutica could also be used in its relative valuation, which is a method of valuing Basilea Pharmaceutica by comparing valuation metrics of similar companies.Basilea Pharmaceutica is currently under evaluation in current valuation category among related companies.
Basilea Fundamentals
Return On Asset | 0.0261 | |||
Profit Margin | 0.01 % | |||
Operating Margin | 0.06 % | |||
Current Valuation | 724.26 M | |||
Shares Outstanding | 11.93 M | |||
Shares Owned By Insiders | 3.07 % | |||
Shares Owned By Institutions | 29.13 % | |||
Price To Earning | 200.00 X | |||
Price To Sales | 4.09 X | |||
Revenue | 148.12 M | |||
Gross Profit | 30.89 M | |||
EBITDA | 2.11 M | |||
Net Income | (6.83 M) | |||
Cash And Equivalents | 140.74 M | |||
Cash Per Share | 11.89 X | |||
Total Debt | 94.54 M | |||
Current Ratio | 1.36 X | |||
Book Value Per Share | (5.67) X | |||
Cash Flow From Operations | (32.02 M) | |||
Earnings Per Share | 0.25 X | |||
Number Of Employees | 177 | |||
Beta | 0.88 | |||
Market Capitalization | 626.06 M | |||
Total Asset | 247.27 M | |||
Retained Earnings | (908 M) | |||
Working Capital | 219 M | |||
Current Asset | 283 M | |||
Current Liabilities | 64 M | |||
Z Score | -0.6 | |||
Net Asset | 247.27 M |
About Basilea Pharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Basilea Pharmaceutica AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Basilea Pharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Basilea Pharmaceutica AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Basilea Pharmaceutica in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Basilea Pharmaceutica's short interest history, or implied volatility extrapolated from Basilea Pharmaceutica options trading.
Pair Trading with Basilea Pharmaceutica
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Basilea Pharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Basilea Pharmaceutica will appreciate offsetting losses from the drop in the long position's value.Moving against Basilea Pink Sheet
0.77 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
0.74 | CSLLY | CSL | PairCorr |
0.71 | CMXHF | CSL Limited | PairCorr |
0.7 | REGN | Regeneron Pharmaceuticals | PairCorr |
0.66 | VRTX | Vertex Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Basilea Pharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Basilea Pharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Basilea Pharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Basilea Pharmaceutica AG to buy it.
The correlation of Basilea Pharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Basilea Pharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Basilea Pharmaceutica moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Basilea Pharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Basilea Pharmaceutica AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Complementary Tools for Basilea Pink Sheet analysis
When running Basilea Pharmaceutica's price analysis, check to measure Basilea Pharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Basilea Pharmaceutica is operating at the current time. Most of Basilea Pharmaceutica's value examination focuses on studying past and present price action to predict the probability of Basilea Pharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Basilea Pharmaceutica's price. Additionally, you may evaluate how the addition of Basilea Pharmaceutica to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |